Product Name | Etoposide | VP-16 | VP-16-213 |
---|---|
CAS | 33419-42-0 |
Formula | C26H33FN4O7 |
MW | 532.56 |
Appearance | White to off-white powder |
Storage condition | 4°C, protect from light |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
25 mg | In-stock | ¥88.00 | Visible after login | |
50 mg | In-stock | ¥146.00 | Visible after login | |
100 mg | In-stock | ¥236.00 | Visible after login | |
250 mg | In-stock | ¥368.00 | Visible after login | |
500 mg | In-stock | ¥466.00 | Visible after login |
Product Name | Etoposide | VP-16 | VP-16-213 |
---|---|
CAS | 33419-42-0 |
Formula | C26H33FN4O7 |
MW | 532.56 |
Appearance | White to off-white powder |
Storage condition | 4°C, protect from light |
Etoposide (formerly VP-16, VP-16213; Toposar; VePesid; Lastet; EPEG), a chemotherapeutic drug used for the treatments of various cancers, is a semisynthetic derivative of the naturally occuring podophyllotoxin which inhibits DNA synthesis via topoisomerase II inhibitory activity.
FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep.
PMID: 31940492 DOI: 10.1016/j.celrep.2019.12.032
Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits.
PMID: 27303923 PMCID: PMC5239464 DOI: 10.18632/oncotarget.9939
PMID: 27473919 DOI: 10.1016/j.tiv.2016.07.018